Myths about where ketamine and esketamine care takes place

Ask people where this kind of depression treatment takes place and you will get confident answers that are often wrong. Some picture a hospital ward, some a pill in the mail, and many assume there is only one way to do it.

Our commissioned poll gathered answers from 443 adults in ten Midwest states and, among other things, asked them to choose a setting for ketamine or esketamine therapy. The answers, and the rules governing each option, undercut several common assumptions. Every survey number here is final, and nothing below is medical advice.

Myth one: everyone would rather do this from home

Home is the default assumption for almost every service now, but not here. A clinic in person was the single most common preference, at 44 percent. A plan that begins at a clinic and later shifts home took 23 percent, telehealth at home 22, while 11 percent were fine either way. Combined, 67 percent wanted a clinic involved at some stage. The appetite for convenience is real, but in this category people want someone in the room, at least at first.

Myth two: the FDA-approved version can be mailed to you

It cannot. Spravato's esketamine carries an FDA approval confined to depression that persisted through earlier treatment, and it moves through a restricted distribution program. The patient takes the spray under supervision at a certified site, is monitored for at least two hours, and should not drive until the next day. Nothing is dispensed for home use. Brain Recovery Centers describes what happens during a Spravato session for anyone who wants the details.

If a service offers to mail you ketamine, it is offering something other than the approved product. That may be legal, but it is a different thing, and you should know which you are choosing.

Myth three: at-home ketamine is the same treatment, just cheaper and easier

At-home programs usually prescribe generic ketamine, often a lozenge or tablet, after a telehealth visit. That is an off-label use of a drug approved as an anesthetic, with no trained person in the room during the session, and its evidence and oversight differ from the approved product.

It is not necessarily cheaper once coverage enters the picture, either. The approved treatment in a certified setting is likelier to be something a plan will consider, often with prior authorization, while at-home programs are frequently self-pay. Price the whole course, not the first month.

Myth four: a clinic means a hospital stay

A certified setting is usually an outpatient office. You arrive, take the dose under supervision, rest through the monitoring period, and leave with a driver the same day. It takes a block of time and a ride, but it is not an admission. For many people that changes the calculation: the obstacle is the drive and the time off, not an overnight stay.

Myth five: any nearby ketamine clinic can give you the approved spray

Not necessarily. Many clinics offer IV ketamine, a different, off-label use, and only sites certified under the restricted program can give Spravato. A sign that says "ketamine" tells you nothing about which they provide, so ask: "Are you a certified site for esketamine, do you offer IV ketamine, or both?" A legitimate clinic answers in one sentence.

Distance does matter. In our survey, 43 percent placed nearness in their top two provider considerations, second only to insurance. But a nearby clinic offering a different product is no substitute for knowing what you are getting.

Myth six: the setting is just a matter of preference

For some options you choose; for the approved product the setting is part of the approval. That shapes which questions matter. If you prefer care at home, the question is not how to get the approved spray delivered but whether an at-home off-label option, or a different treatment, suits you, and a clinician is the person to ask. Notably, a drug-free route mattered to 64 percent of respondents, yet barely a quarter knew what TMS was; transcranial magnetic stimulation is another in-office option some people ask about.

Myth seven: people will pay to skip the insurance hassle

Many assume patients will happily pay to skip paperwork. Our sample disagreed. Half would take the insurance route despite more hoops; the rest split between paying for a simpler path (23 percent) and not knowing (26 percent).

Coverage dominated elsewhere too. Insurance ranked first or second among provider factors for 85 percent of the sample, and for 65 percent it would decide or heavily shape whether they pursued treatment. For many people, where care happens will be decided by what their plan covers, not by convenience.

Why these myths persist

Partly because so few people know the approved option exists. Among our respondents, Spravato was a mystery to 73 percent; just 6 percent were able to describe the drug. When a name is unfamiliar, people fill the gap with whatever they have seen most, often an ad for an at-home program or a news story about a clinic.

More advertising is not the fix. Asked what would get them to try this treatment, respondents gave ads 2 percent and their own doctor's recommendation 74 percent.

What to do with this

• If a provider mentions ketamine, ask which arrangement they mean: supervised esketamine at a certified site, IV ketamine at a clinic, or ketamine at home.
• Ask where it happens and how often before anything else about logistics.
• Call your insurer before comparing clinics.
• Ask your doctor whether any of these suits you at all.

Whether any option fits is for a clinician with your full history to judge, and no setting can promise a result.

If thoughts of suicide are pressing on you, call or text 988 from anywhere in the country. The Lifeline answers around the clock, free and in confidence.

Methodology

The publisher commissioned and funded this research. Pollfish study 395586438 drew on the company's consumer panel, and its final day of fieldwork was June 23, 2026. Its 443 completed questionnaires came from adults 18 to 64 across ten Midwest states and are reported here only as top-line percentages, with no subgroup analysis. Multi-select questions are shares of respondents. The panel's validation is complete, and every figure reflects it.